Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT03000179
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer
Not Applicable
Terminated
- Conditions
- Small Cell Lung CarcinomaNon-Small Cell Lung Carcinoma
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02937402
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Hatha Yoga in Breast Cancer Survivors
Not Applicable
Terminated
- Conditions
- Breast CarcinomaLymphedema
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT02923037
- Locations
- 🇺🇸
Vanderbilt University School of Nursing, Nashville, Tennessee, United States
PET Imaging of Ovarian Carcinoma With 18F-FSPG
Early Phase 1
Withdrawn
- Conditions
- Stage IIIA Ovarian CancerStage IIIA Primary Peritoneal CancerStage IV Ovarian CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian CancerStage IIIA Fallopian Tube CancerStage IIIB Ovarian CancerStage IIIB Fallopian Tube CancerStage IIIB Primary Peritoneal CancerStage IIIC Primary Peritoneal Cancer
- Interventions
- Drug: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)Procedure: Positron Emission TomographyOther: Laboratory Biomarker Analysis
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT02872519
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Phase 2
Completed
- Conditions
- Blastoid Variant Mantle Cell LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Follicular LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Hodgkin LymphomaRecurrent Follicular LymphomaRefractory Hodgkin LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT02869633
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
Phase 2
Completed
- Conditions
- Hematopoietic Cell Transplantation RecipientMalignant NeoplasmInfluenza
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 170
- Registration Number
- NCT02860039
- Locations
- 🇺🇸
UCSF Children's Hospital, San Francisco, California, United States
🇺🇸Children's Mercy Hospital, Kansas City, Missouri, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Visually Enhanced Education About Prostate Cancer
Not Applicable
Completed
- Conditions
- Stage I Prostate CancerStage II Prostate CancerStage III Prostate Cancer
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT02846870
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Phase 1
Withdrawn
- Conditions
- Multiple Endocrine Neoplasia Type 1Functional Pancreatic Neuroendocrine TumorMalignant SomatostatinomaMetastatic Carcinoid TumorMultiple Endocrine Neoplasia Type 2AStage IIIA Merkel Cell CarcinomaStage IIIB Merkel Cell CarcinomaStage IVB Thyroid Gland Medullary CarcinomaVIP-Producing Neuroendocrine TumorMerkel Cell Carcinoma
- Interventions
- Other: Pharmacological StudyOther: Laboratory Biomarker Analysis
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT02831179
Chemoprevention of Gastric Carcinogenesis
Phase 2
Completed
- Conditions
- Gastric CancerGastric Intestinal Metaplasia
- Interventions
- Other: Eflornithine placebo
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 91
- Registration Number
- NCT02794428
- Locations
- 🇭🇳
Ministry of Health, Hospital de Occidente, Copán, Honduras
🇵🇷University of Puerto Rico, Comprehensive Cancer Center, San Juan, Puerto Rico
Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
Recruiting
- Conditions
- Refractory Mycosis FungoidesRecurrent Mycosis FungoidesStage II Mycosis FungoidesStage III Mycosis FungoidesStage I Mycosis Fungoides
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT02702310
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States